Beyond Biotech - the podcast from Labiotech

BioSenic developing severe knee osteoarthritis treatment

Feb 2, 2024

BioSenic, a clinical-stage company, discusses their late-clinical asset JTA-004 for severe knee osteoarthritis. They share data on its safety and efficacy at an international congress. Topics covered include the mechanism of action of JTA-004, attending events, potential administration frequency, other companies working on osteoarthritis, and future steps.

31:43

Episode guests

BioSenic

AI Summary

AI Chapters

Episode notes

Podcast summary created with Snipd AI

Quick takeaways

JTA-004, developed by BioSenic, has shown potential in targeting the specific cluster of patients with severe and inflammatory osteoarthritis, offering a promising option for treating this condition.

Biosenic is exploring the potential of arsenic trioxide as a treatment for autoimmune diseases, such as systemic sclerosis and lupus, due to its effectiveness in treating chronic graft versus host disease and its ability to act on multiple pathways and cell types.

Deep dives

Treatment for Severe Knee Osteoarthritis

Biosenic is a company that is developing a treatment called JTA-004 for severe knee osteoarthritis. This treatment is an intra-articular viscos supplement that aims to provide relief for patients with inflammatory osteoarthritis. Currently, there is no effective treatment for osteoarthritis, with existing options only focusing on pain relief. However, JTA-004 has shown potential in targeting the specific cluster of patients with severe and inflammatory osteoarthritis. Its compound, Clonidine, acts as both an anesthetic and an anti-inflammatory agent, making it a promising option for treating this condition.

Introduction

3min

Developing a JTA Technology for Severe Inflammatory Osteoarthritis

5min

ALOB Cell Therapy for Bone Repair: Clinical Trials and Challenges

4min

Exploring the Mechanisms of JTA-004 in Treating Severe Inflammatory Osteoarthritis

3min

Analyzing a Failed Clinical Trial for Knee Osteoarthritis Treatment

16min

BioSenic, a Belgian clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, will share data on its late-clinical asset JTA-004 at the Osteoarthritis Research Society International (OARSI) World Congress 2024 in Vienna, Austria.

The post hoc analysis of a phase 3 study found that a single injection of JTA-004 was safe and efficacious for patients with a newly characterized severe inflammatory subtype of knee osteoarthritis (OA).

This week on the podcast, we talk about the treatment with BioSenic chief scientific officer and chief operating officer, Dr Carole Nicco.

00:52-03:19: About BioSenic
03:19-07:34: What is osteoarthritis?
07:34-11:45: What is ALLOB?
11:45-15:03: What is JTA-004?
15:04-17:14: What will you be presenting at the OARSI event?
17:14-20:20: How useful is attending events for BioSenic?
20:20-21:04: How often will JTA-004 need to be administered?
21:04-24:08: Are other companies working on osteoarthritis?
24:08-26:26: What stage are your arsenic trioxide trails at?
26:26-29:50: Will this be useful in treating other autoimmune diseases?
29:50-31:08: What are the next steps?

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more